We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Brief Report |

High-Dose Intravenous Pulse Methotrexate in Patients With Eosinophilic Fasciitis ONLINE FIRST

Jorre S. Mertens, MD1,2; Manon C. Zweers, MD, PhD1; Wietske Kievit, PhD3; Hanneke K. A. Knaapen, MD4; Martijn Gerritsen, MD, PhD5; Timothy R. D. J. Radstake, MD, PhD2,6; Frank H. J. van den Hoogen, MD, PhD4; Marjonne C. W. Creemers, MD, PhD7; Elke M. G. J. de Jong, MD, PhD1
[+] Author Affiliations
1Department of Dermatology, Radboud University Medical Centre, Nijmegen, the Netherlands
2Laboratory of Translational Immunology, University Medical Centre Utrecht, Utrecht, the Netherlands
3Department of Epidemiology, Health Evidence, Radboud University Medical Centre, Nijmegen, the Netherlands
4Department of Rheumatology, Radboud University Medical Centre & Sint Maarstenskliniek, Nijmegen, the Netherlands
5Department of Rheumatology, Westfriesgasthuis, Hoorn, the Netherlands
6Department of Rheumatology and Clinical immunology, University Medical Centre Utrecht, Utrecht, the Netherlands
7Department of Rheumatology, Jeroen Bosch Hospital-Hertogenbosch, the Netherlands
JAMA Dermatol. Published online August 17, 2016. doi:10.1001/jamadermatol.2016.2873
Text Size: A A A
Published online

Importance  Eosinophilic fasciitis (EF) is a connective tissue disorder in which conventional treatment leads to disappointing results in a proportion of patients. Therefore, we investigated high-dose intravenous (IV) pulse methotrexate (MTX) as a treatment for EF.

Objective  To examine safety and effects of monthly high-dose IV pulse MTX in EF.

Design, Setting, and Participants  For this prospective single-arm study, we recruited 12 patients diagnosed with biopsy specimen–proven EF between 2006 and 2009 from the Department of Dermatology and Rheumatology at the Radboud University Medical Centre.

Interventions  Intravenous MTX (4 mg/kg) monthly for 5 months with folinic acid rescue 24 hours after MTX administration.

Main Outcomes and Measures  The primary outcome was improvement of the modified skin score at month 5 vs baseline. Secondary outcomes were durometry, range of motion, visual analog scale scores for disease activity, and 36-Item Short Form Survey health questionnaires.

Results  Overall, 12 patients (11 women between 37-69 years old) received a median (range) monthly dose of 288 (230-336) mg MTX. Median (range) modified skin score improved from 17.5 (8.0-24.0) at baseline to 8.5 (1.0-20.0) at month 5 (P = .001). Secondary outcome measures improved significantly, except for durometer scores and range of motion of the elbows. Adverse events included gastrointestinal symptoms (n = 9), mild stomatitis (n = 5), and alopecia (n = 4).

Conclusions and Relevance  High-dose IV pulse MTX is a safe and effective treatment option in EF.

Trial Registration  clinicaltrials.gov Identifier: NCT00441961

Figures in this Article


Place holder to copy figure label and caption
Skin Induration and Improvement Scored With Modified Skin Score

A, The primary outcome measure, skin induration, scored with modified skin score (mSS) at baseline and at month 5 for each patient. B, Improvement in mSS at month 5 compared with baseline (Δ mSS); Δ mSS for MTX-naive (left column) and MTX nonnaive (right column) are displayed by scatter plot and median.Comparison of median Δ mSS scores between the 2 subgroups showed no significant difference (P = .97). For 2 patients (Nos. 6 and 8) mSS scores were missing at month 5 and observations from month 4 were carried forward.

Graphic Jump Location




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections

Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice, 3rd ed